Brief: Medivir And Shijiazhuang Yuanmai Biotechnology Sign Licensing Agreement

Medivir AB

24/02/2020 15:03

Feb 24 (Reuters) - Medivir AB  MVIRb.ST :
    * MEDIVIR AND SHIJIAZHUANG YUANMAI BIOTECHNOLOGY SIGN
LICENSING
AGREEMENT REGARDING MANUFACTURING AND SALES OF XERCLEAR® IN
CHINA
    * AFTER MARKET REGISTRATION AND PRODUCTION IN CHINA, MEDIVIR
WILL
RECEIVE A FIXED ROYALTY FOR EACH UNIT SOLD AND AGREEMENT
GUARANTEES A MINIMUM SALE DURING FIRST THREE YEARS ON MARKET
AMOUNTING TO SINGLE-DIGIT MILLION AMOUNTS IN SEK
    * AGREEMENT GIVES SYB RIGHT TO REGISTER, MANUFACTURE AND
MARKET
PRODUCT IN CHINA

Source text for Eikon:  ID:nWkrr7hFS 
Further company coverage:  MVIRb.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))